| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 11/06/2003 | WO2003034900A3 Sterile, breathable patch for treating wound pain |
| 11/06/2003 | WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 11/06/2003 | WO2003015714A3 Compositions and therapeutic methods for viral infection |
| 11/06/2003 | WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 11/06/2003 | WO2003011421A3 Emulsifier mixture |
| 11/06/2003 | WO2003008555A3 Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| 11/06/2003 | WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c |
| 11/06/2003 | WO2003000294A8 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| 11/06/2003 | WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin |
| 11/06/2003 | WO2002094845A3 Method for stabilising of nucleic acids |
| 11/06/2003 | WO2002085328A3 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
| 11/06/2003 | WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy |
| 11/06/2003 | WO2002072100A3 Pharmaceutical composition containing pde v inhibitors and surfactants |
| 11/06/2003 | WO2002069993A8 Pharmaceutical composition made of cannabis extracts |
| 11/06/2003 | WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 11/06/2003 | WO2002060491A3 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 11/06/2003 | WO2002055020A9 Topical testosterone formulations and associated methods |
| 11/06/2003 | WO2002043770A3 Homing peptide multimers, their preparation and uses |
| 11/06/2003 | WO2002040039A3 In vivo use of water absorbent polymers |
| 11/06/2003 | WO2002038208A9 Device and method for the cessation of smoking |
| 11/06/2003 | WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 11/06/2003 | WO2002024891A9 B7-like molecules and uses thereof |
| 11/06/2003 | WO2002003848A8 Method for opening the blood-brain barrier |
| 11/06/2003 | US20030208249 Energy-activated targeted cancer therapy |
| 11/06/2003 | US20030208049 Comprising a molecule bound to Tumor necrosis factor (TNF) and methods of therapy utilising TNF and molecules active against TNF |
| 11/06/2003 | US20030208047 Relates to ligands which bind to human tumour necrosis factor alpha (TNF) to modify the biological activity |
| 11/06/2003 | US20030208046 Pseudo native chemical ligation |
| 11/06/2003 | US20030207946 Also comprises electrokinetic stabilizer such as lysine, arginine or histidine, mono-/di-ethanolamine, sodium (bi)carbonate, tromethamine and/or sodium phosphate |
| 11/06/2003 | US20030207936 Comprises fatty ester modified-polyoxyethylene glycol solubilizers |
| 11/06/2003 | US20030207907 Deliverying antirestenoic compound such as an antiproliferative, immunosuppressive, or antiinflammatory drug, particularly rapamycin, tacrolimus, paclitaxel, dexamethasone, or an active analog or derivative thereof |
| 11/06/2003 | US20030207797 Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful |
| 11/06/2003 | US20030207772 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 11/06/2003 | US20030207469 Via immunoassay; low cross-reactivity with ephedrine and other compounds; antibody produced by a methylene dioxyphenyl derivative of agiven structure |
| 11/06/2003 | US20030207447 Used to distinguish between arterial endothelial cells (arteries) and venous endothelial cells (veins) |
| 11/06/2003 | US20030207252 Treatment and diagnostic drugs, kits |
| 11/06/2003 | US20030207247 For reducing risks due to cellular transfusion immune response |
| 11/06/2003 | US20030206993 Formed by cooling to brittleness; grinding to powder; mixing with supplement; granulation; and forming tablets |
| 11/06/2003 | US20030206970 Ophthalmic compositions containing galactomannan polymers and borate |
| 11/06/2003 | US20030206966 Methods of inducing apoptosis and modulating metalloproteinases |
| 11/06/2003 | US20030206961 Production of purified, parenterally administrable starch by washing to remove surface-localized proteins, lipids and endotoxins; and effecting molecular weight reduction by acid hydrolysis |
| 11/06/2003 | US20030206960 Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| 11/06/2003 | US20030206958 Chitosan biopolymer for the topical delivery of active agents |
| 11/06/2003 | US20030206956 Topical treatment of prevention of ocular infections |
| 11/06/2003 | US20030206954 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 11/06/2003 | US20030206949 Dispersible phospholipid stabilized microparticles |
| 11/06/2003 | US20030206947 Low viscosity hydroxypropylcellulose with an average molecular weight of 30,000-100,000 and with a molar degree of substitution of at least 3 |
| 11/06/2003 | US20030206946 Methods for therapy of connective tissue disease |
| 11/06/2003 | US20030206943 Lotion is applied to a portion of the body facing surface of the topsheet that has a level of hydrophobicity equal or greater than that of said topsheet. |
| 11/06/2003 | US20030206942 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent |
| 11/06/2003 | US20030206941 Fast dissolving orally consumable films |
| 11/06/2003 | US20030206939 Treating and/or preventing dental caries and/or tooth erosion, dental sensitivity, mouth odor, osteoporosis, calculus formation or gingivitis; recrystallising and/or remineralising enamel and/or dentine; buffering plaque |
| 11/06/2003 | US20030206933 Treatment of keratin fibers and skin. |
| 11/06/2003 | US20030206929 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides |
| 11/06/2003 | US20030206917 Transferring a protein to a cell by coating the cell surface with a lipidated protein; and contacting said cell with a fusion protein having affinity for said lipidated protein and capable of binding to a cell surface receptor |
| 11/06/2003 | US20030206911 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target |
| 11/06/2003 | US20030206910 Poloxamer 188, Poloxamer 237, Poloxamer 338, Poloxamer 124, Poloxamer 401, Tetronic 904, Tetronic 908, Tetronic 1107 or Tetronic 90R4; especially for treating chronic hepatitis and cancer |
| 11/06/2003 | US20030206900 Vectors derived from antibodies for transferring substances into cells |
| 11/06/2003 | US20030206887 RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| 11/06/2003 | US20030206881 Phospholipidic composition as well as the use thereof |
| 11/06/2003 | US20030206875 Compositions for treating biofilm |
| 11/06/2003 | US20030206869 Delivery of antidepressants through an inhalation route |
| 11/06/2003 | US20030206867 Spray that delivers unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means. |
| 11/06/2003 | US20030206865 Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy |
| 11/06/2003 | US20030206864 Embolic agents visible under ultrasound |
| 11/06/2003 | US20030206858 Metal complex-containing pharmaceutical agents |
| 11/06/2003 | CA2711709A1 Oral care compositions containing ovomucin |
| 11/06/2003 | CA2496454A1 Transdermal analgesic systems with reduced abuse potential |
| 11/06/2003 | CA2487245A1 An injection made from ixeris sonchifolia hance for treatment of cardio-cerebral vascular diseases and fundus diseases and method of producing thereof |
| 11/06/2003 | CA2483980A1 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 11/06/2003 | CA2483265A1 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 11/06/2003 | CA2483102A1 Treatment and prevention of pulmonary conditions |
| 11/06/2003 | CA2482941A1 Microparticle pharmaceutical compositions for intratumoral delivery |
| 11/06/2003 | CA2482936A1 Capsule preparation |
| 11/06/2003 | CA2482932A1 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same |
| 11/06/2003 | CA2479943A1 Method for reduction of residual organic solvent in carbomer |
| 11/06/2003 | CA2478680A1 Chimeric hybrid analgesics |
| 11/05/2003 | EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum |
| 11/05/2003 | EP1358874A1 Peptide/lipid complex formation by co-lyopholization |
| 11/05/2003 | EP1358327A2 Proteins and nucleic acids encoding same |
| 11/05/2003 | EP1358318A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| 11/05/2003 | EP1358236A2 Liquid dispersion polymer compositions, their preparation and their use |
| 11/05/2003 | EP1358200A2 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| 11/05/2003 | EP1358195A2 Acylated cellobiose compounds |
| 11/05/2003 | EP1358153A1 Ophthalmic compositions for treating ocular hypertension |
| 11/05/2003 | EP1357977A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 11/05/2003 | EP1357975A1 Medicament compositions with negligible side-effects containing betamimetics |
| 11/05/2003 | EP1357974A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 11/05/2003 | EP1357937A2 Use of botuline toxin to obtain a product to be used in articular pathologies, particularly coxarthrosis, epicondylitis and rotator muscle cap pathology |
| 11/05/2003 | EP1357930A2 Histidine-rich glycoprotein |
| 11/05/2003 | EP1357928A2 A novel pharmaceutical compound and methods of making and using same |
| 11/05/2003 | EP1357920A2 Compositions and method of tissue superoxygenation |
| 11/05/2003 | EP1357903A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO b]THIOPHENE AND SALTS THEREOF |
| 11/05/2003 | EP1357899A2 Oral itraconazole formulations and methods of making the same |
| 11/05/2003 | EP1357897A2 Delivery of biologically active agents |
| 11/05/2003 | EP1357895A2 Vaccine composition and stabilisation method |
| 11/05/2003 | EP1357893A2 Acid cosmetic, dermatological and pharmaceutical agents |
| 11/05/2003 | EP1357892A1 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same |
| 11/05/2003 | EP1357873A2 Therapeutic film forming composition and treatment system therefor |
| 11/05/2003 | EP1357870A1 Bioadhesive cell foam film of sustained-release delivery |
| 11/05/2003 | EP1357855A2 Ophthalmic compositions for treating ocular hypertension |